Veeda Clinical Research Share Price

Price Chart

• Overview: Veeda Clinical Research, a leading CRO in India, has been operating for two decades, providing comprehensive services across various stages of drug development including preclinical, early phase, and late-phase clinical trials, bioanalytical assessment, and drug launch.
  
• Technical Expertise: The organization specializes in pharmacokinetics (PK) studies and trials for generic molecules, new chemical entities, large molecules, and biosimilars, with an impressive ISR (Incurred Sample Reanalysis) rate of >95%, surpassing the USFDA recommended rate of 67%.
  
• Service Spectrum: Veeda offers bioavailability (BA) & bioequivalence (BE) studies, bioanalytical research, medical writing, pharmacovigilance, preclinical trials, clinical trials (Phase I to Phase III), biosimilars, biopharmaceutics, data science, and post-marketing surveillance.
  
• Bioanalytical Research: Developed over 1,000 bioanalytical methods, including 860 generics, 70+ complex generics, 30+ large molecule assays, and 70+ in-house methods.
  
• Clinical Trial Expertise: Provides a range of clinical development programs to pharmaceutical, biotech, generic, and medical device companies, ensuring fully ICH-GCP compliant operations, including early phase (Phase I) and late phase (Phase II & III) clinical trials.
  
• Biosimilars: Through a joint venture with Ingenuity Biosciences, Veeda offers specialized clinical services including PK antidrug antibodies, neutralizing antibodies, and biomarker assays, as well as characterization and comparability testing.
  
• Global Reach: With a significant client base in North America, Europe, and Asia, Veeda generates approximately 70% of its revenue from overseas clients.
• Facilities: Operates around 7 facilities, each catering to different stages of the drug development cycle, and has a subsidiary, Bioneeds, for preclinical research, providing an operational edge.
  
• Clients: Veeda Clinical Research has completed studies for numerous high-profile clients worldwide, including Dr. Reddy’s Laboratories Limited, Mankind Pharma Limited, and Granules India Limited in India; Laboratorios Liconsa, S.A (Chemo) in Europe; Novugen Pharma (Malaysia) SDN. BHD. in Malaysia; Sunshine Lake Pharma Co. Ltd and Ǫilu Pharmaceutical Co., Ltd in China; and Upsher-Smith Laboratories LLC and Osmotica Pharmaceutical US LLC in the USA.